Ahmed A, Salahuddin N, Ahsan T, Afsar S, Nasir N, Farooqui S, Chaoudri A N, Akhtar M A, Agha I, Nagi N
Aga Khan University Hospital, Karachi, Pakistan.
Clin Ther. 1992 Nov-Dec;14(6):825-8.
Enoxacin 400 mg twice daily was given orally to 40 patients who had Salmonella typhi- or Salmonella paratyphi-positive blood or bone marrow cultures. One patient was switched to parenteral therapy within 48 hours of study enrollment, but the remaining 39 patients were given enoxacin for 10 to 14 days. All 39 patients were cured by enoxacin, even though 23 (58.9%) strains were resistant to cotrimoxazole and 16 (41%) strains were multiply resistant to ampicillin, chloramphenicol, and cotrimoxazole. No adverse events necessitated the interruption of therapy. In this study, enoxacin was well tolerated and efficacious in the treatment of typhoid fever.
对40例血培养或骨髓培养伤寒沙门菌或副伤寒沙门菌呈阳性的患者，口服给予依诺沙星，剂量为每日2次，每次400mg。1例患者在研究入组后48小时内改为肠外治疗，但其余39例患者接受依诺沙星治疗10至14天。所有39例患者均被依诺沙星治愈，尽管有23株（58.9%）对复方新诺明耐药，16株（41%）对氨苄西林、氯霉素和复方新诺明多重耐药。没有不良事件导致治疗中断。在本研究中，依诺沙星治疗伤寒热耐受性良好且疗效显著。
